An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors

Trial Profile

An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Brain cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Jun 2016 Disease descriptor has been changed to brain tumor. Initially it was brain metastases, bladder-cancer, breast-cancer and non-small-cell-lung-cancer.
    • 21 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top